Tourmaline Bio Inc TRML
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $25.02
- Day Range
- $24.59–25.40
- 52-Week Range
- $9.20–48.13
- Bid/Ask
- $24.85 / $25.12
- Market Cap
- $644.37 Mil
- Volume/Avg
- 121,796 / 243,182
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 58
- Website
- https://www.tourmalinebio.com
Comparables
Valuation
|
Metric
|
TRML
|
SWTX
|
ARVN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.90 | 4.31 | 2.83 |
Price/Sales | — | 25.81 | 11.73 |
Price/Cash Flow | — | — | — |
Price/Earnings
TRML
SWTX
ARVN
Financial Strength
|
Metric
|
TRML
|
SWTX
|
ARVN
|
|---|---|---|---|
Quick Ratio | 45.52 | 7.49 | 3.57 |
Current Ratio | 46.87 | 7.91 | 3.62 |
Interest Coverage | — | — | — |
Quick Ratio
TRML
SWTX
ARVN
Profitability
|
Metric
|
TRML
|
SWTX
|
ARVN
|
|---|---|---|---|
Return on Assets (Normalized) | −12.10% | −32.86% | −22.33% |
Return on Equity (Normalized) | −14.03% | −37.78% | −47.53% |
Return on Invested Capital (Normalized) | −14.00% | −42.13% | −54.26% |
Return on Assets
TRML
SWTX
ARVN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Xcstbmpxs | Lyxj | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Qddsmjss | Cmkks | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Csvqxhn | Wjlzby | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wxmkrrg | Wtsls | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Gmfjvsxh | Qkrqp | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Rsklybc | Nstfh | $28.1 Bil | |||
| Moderna Inc
MRNA
| Spfdqwk | Lwvhb | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Wqyjvbjk | Lyx | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xqqsklvmr | Kjpgjhj | $13.4 Bil | |||
| Incyte Corp
INCY
| Qkfvhsmq | Fjxsz | $12.7 Bil |
United States